monoclonal

Monoclonal antibody formulation ensures stability and efficacy. Biointron outlines strategies to design formulations that preserve quality and therapeutic impact.

Hybridoma technologies laid the foundation for antibody discovery. Biointron explains conventional methods and their lasting value in monoclonal development.

Infliximab was the first antibody for IBD. Biointron reviews its approval, mechanism, and impact on advancing therapeutic monoclonal antibodies.

Anti-amyloid antibodies are designed to target and remove amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease. These plaques are toxic protein clusters believed to disrupt communication between neurons, leading to cell death and cognitive decline. By binding to amyloid-beta, these antibodies aim to neutralize or clear the plaques, potentially slowing disease progression.

Hybridoma technology pioneered monoclonal antibody production. Biointron reviews the process and its ongoing relevance in antibody discovery and development.

Antibody drug development has revolutionized biomedicine. Biointron highlights stages from discovery to approval that shape antibody-based therapies.

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.

Antibody therapeutics power modern medicine. Biointron reviews monoclonals, bispecifics, and next-gen formats advancing treatment across multiple diseases.

Monoclonal antibodies are cornerstones of biotech. Biointron reviews their discovery, mechanisms, and applications in diagnostics and therapeutic innovation.

Antibodies are versatile research tools. Biointron highlights their applications in diagnostics, validation, and experimental discovery across biotechnology.

In August, the US FDA approved Galderma’s Nemluvio (nemolizumab) for adult patients living with prurigo nodularis (PN). Nemluvio is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in (PN). Prurigo nodularis is a chronic skin condition that affects approximately 181,000 patients in the United States

Hepatitis B virus (HBV) infection is a major global health issue, driven by high levels of immunosuppressive viral antigens, the host immune system's failure to effectively control the virus, and the immunosuppressive environment of the liver. Existing therapies have limited effectiveness in eliminating the hepatitis B surface antigen (HBsAg).

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

Antibody-antibiotic conjugates fight resistant bacteria with precision. Biointron highlights how AACs combine antibody targeting with antibiotic power for infections.

Ozempic, a brand name for the drug semaglutide, was originally developed to manage type 2 diabetes by improving blood sugar control. As a GLP-1 receptor agonist, it mimics a hormone that regulates glucose metabolism and appetite. Beyond its success in diabetes treatment, Ozempic has garnered signifi